ANDA 208522, held by Actavis Laboratories FL. Carbidopa; Levodopa.
As of Nov 21, 2026, ANDA 208522 (Carbidopa and Levodopa), held by Actavis Laboratories FL, was first approved by FDA on Nov 2, 2026, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 2, 2026 | Original application | Approved | None posted |
| Carbidopa and Levodopa23.75MG;95MG ยท capsule, extended release;oral | Carbidopa; Levodopa | Rx |
| Carbidopa and Levodopa36.25MG;145MG ยท capsule, extended release;oral | Carbidopa; Levodopa | Rx |
| Carbidopa and Levodopa48.75MG;195MG ยท capsule, extended release;oral | Carbidopa; Levodopa | Rx |
| Carbidopa and Levodopa61.25MG;245MG ยท capsule, extended release;oral | Carbidopa; Levodopa | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters